RRT8 Antibody

What is the RPAT8 antibody and what are its primary applications?

The RPAT8 antibody is a mouse IgG1 Kappa monoclonal antibody specifically targeting CD8, a membrane glycoprotein expressed on cytotoxic T-cells that interacts with MHC class I processed antigens. CD8 plays crucial roles in regulating T-cell activation and differentiation. The antibody is primarily validated for flow cytometry (FACS) applications with human samples .

For effective application in flow cytometry, researchers should use approximately 0.5 μg per 10^6 cells. The antibody is typically supplied in PBS containing 0.05% BSA and 0.05% sodium azide, with standard preparations available as 25 μg in 50 μl or 100 μg in 200 μl formats .

How should RPAT8 antibody be stored and handled to maintain its functionality?

For short-term storage (up to 6 months), the RPAT8 antibody should be stored at 4°C. For long-term storage, maintaining the antibody at -20°C is recommended. It's critical to avoid repeated freeze-thaw cycles as these can degrade antibody quality and compromise experimental results .

When working with this antibody, researchers should be aware that the storage solution contains sodium azide, which is highly toxic. Appropriate laboratory safety protocols should be followed when handling the reagent, including proper disposal procedures and avoiding ingestion or contact with skin .

What is the biological significance of the CD8 target recognized by RPAT8?

CD8 exists in two primary isoforms (25 and 21 kDa) and can function either as a homodimer (two alpha chains) or as a heterodimer (one alpha and one beta chain). In thymus-derived T-cells, CD8 typically consists of a disulfide-linked alpha/CD8A and beta/CD8B chain, though it can sometimes be expressed as a CD8A homodimer .

CD8 expression patterns are tissue-specific, with high expression in T lymphocytes, peripheral blood T-lymphocytes, thymus, spleen, and lymphocyte populations. Beyond conventional T-cells, certain subsets of natural killer cells, memory T-cells, intraepithelial lymphocytes, monocytes, and dendritic cells express CD8A homodimers. Notably, CD8A is expressed at the cell surface of plasmacytoid dendritic cells following herpes simplex virus-1 stimulation, suggesting its role in antiviral responses .

How do IgG subclasses differ in antibody responses, and what implications does this have for experimental design?

IgG subclasses demonstrate distinct characteristics in antibody responses that significantly impact experimental outcomes. Research on factor VIII antibodies revealed that IgG4 and IgG1 were the predominant subclasses in patients with inhibitors, while IgG4 was completely absent in patients without inhibitors and healthy subjects . This differentiation points to distinct immune regulatory pathways associated with specific IgG subclasses.

When designing antibody experiments, researchers should consider:

• Subclass-specific detection methods to fully characterize responses

• Including appropriate controls that account for isotype variations

• Using sensitive ELISA techniques that can distinguish between neutralizing and non-neutralizing antibodies

• Analyzing both prevalence and titers to fully understand antibody dynamics

These considerations are particularly important when studying pathological conditions where antibody subclass distribution may differ markedly from healthy individuals, potentially revealing mechanistic insights into disease processes .

What approaches can be used to design antibodies with customized specificity profiles?

Modern antibody design leverages computational techniques to achieve customized specificity profiles. A biophysics-informed modeling approach can be employed to identify distinct binding modes associated with specific ligands, enabling the prediction and generation of antibody variants with desired specificity characteristics .

This process typically involves:

• Initial phage display experiments selecting antibodies against various ligand combinations

• High-throughput sequencing of selected antibody libraries

• Computational modeling to disentangle multiple binding modes associated with specific ligands

• Predicting novel antibody sequences with tailored specificity profiles

• Experimental validation of computationally designed variants

This approach has successfully generated antibodies with either highly specific affinity for particular target ligands or cross-specificity for multiple target ligands. The combination of biophysics-informed modeling with extensive selection experiments provides a powerful toolset applicable beyond antibodies, offering methods for designing proteins with desired physical properties .

How can researchers identify and characterize T-cell epitopes that might interact with antibodies in complex immunological settings?

Identifying T-cell epitopes requires comprehensive methodological approaches. Recent research on influenza B virus CD8+ T-cell epitopes demonstrates effective strategies:

• Utilize immunopeptidomics to identify peptides presented by specific HLA allomorphs

• Screen for epitope conservation across viral strains (targeting those with >99% conservation)

• Assess immunogenicity by stimulating PBMCs with peptide pools followed by measurement of cytokine production (IFN-γ and TNF)

• Employ tetramer staining to identify memory T-cells specific to the epitopes

• Analyze T-cell receptor repertoires associated with specific epitopes to understand recognition mechanisms

This systematic approach has successfully identified multiple conserved T-cell epitopes restricted by different HLA types, providing potential targets for vaccine development and immunotherapeutic interventions .

How should researchers properly cite and identify antibodies in scientific publications to ensure reproducibility?

To ensure reproducibility in antibody research, proper citation and identification are essential. The Research Resource Identification Initiative recommends including Research Resource Identifiers (RRIDs) for all key resources, including antibodies. For antibodies, publications should include:

• Complete vendor information including catalog number

• The specific RRID in the format: "RRID: AB_X" (where X is the unique identifier)

• Complete characterization information (species, isotype, clonality)

For example: "Sections were stained with a rabbit polyclonal antibody against ERK1 (Abgent Cat# AP7251E, RRID: AB_2140114)."

To obtain an RRID, researchers should:

• Visit https://scicrunch.org/resources

• Enter search terms (narrow search by including vendor name and/or catalog number)

• Select the appropriate resource and note the RRID

• Include the RRID in the methods section of the manuscript

This standardized reporting facilitates resource tracking across the literature, enables systematic reviews, and supports experimental reproducibility in the scientific community .

What validation strategies should be employed when using antibodies for flow cytometry applications?

When validating antibodies for flow cytometry applications, researchers should implement a comprehensive approach:

• Titration experiments: Determine optimal antibody concentration (e.g., 0.5 μg/10^6 cells for RPAT8) to maximize signal-to-noise ratio .

• Specificity controls:

  • Include isotype controls matching the primary antibody's isotype (Mouse IgG1 Kappa for RPAT8)

  • Test antibody on cell populations known to be negative for the target

  • When possible, use genetic knockout samples as definitive negative controls

• Multiparameter validation:

  • Confirm expected co-expression patterns with other markers

  • Verify that staining patterns correspond to known biological distributions

• Compensation and panel design:

  • Properly compensate for spectral overlap when using multiple fluorochromes

  • Design panels that minimize fluorophore interference

• Functional correlation:

  • When applicable, correlate marker expression with known functional readouts

  • For T-cell studies, correlate CD8 expression with cytotoxic activity or cytokine production

Proper validation ensures reliable and reproducible results, particularly when studying complex immune cell populations where precise phenotyping is critical .

How can phage display be effectively employed to select antibodies with desired specificities?

Phage display represents a powerful technique for selecting antibodies with specific binding profiles. An effective experimental approach involves:

• Library design: Create antibody libraries with systematic variation in key binding regions, such as the complementarity-determining regions (CDRs). Focused libraries with variations in CDR3 can be particularly effective, as demonstrated in studies using libraries where four consecutive positions are systematically varied .

• Selection strategy:

  • Implement multiple rounds of selection (biopanning) against target ligands

  • Use negative selection steps to remove non-specific binders

  • Employ different combinations of ligands to identify cross-reactive and specific antibodies

• High-throughput analysis:

  • Sequence selected antibody pools using next-generation sequencing

  • Analyze enrichment patterns to identify promising candidates

  • Apply computational models to predict binding modes and specificities

• Experimental validation:

  • Express selected antibodies as recombinant proteins

  • Verify binding properties using techniques like ELISA, surface plasmon resonance, or flow cytometry

  • Test functionality in relevant biological assays

This integrated approach has successfully yielded antibodies with customized specificity profiles, including both highly specific binders for individual targets and cross-reactive antibodies that recognize multiple related epitopes .

What computational approaches enable the design of antibodies with nanomolar binding affinities?

Computational antibody design has advanced significantly, enabling the creation of high-affinity binders. Effective computational design strategies include:

• Template-based redesign: Starting with well-characterized antibodies that bind related targets (e.g., SARS-CoV-1 antibodies redesigned to bind SARS-CoV-2) .

• Structural modeling approaches:

  • RosettaAntibodyDesign (RAbD) can be employed to model antibody-antigen interactions

  • In silico mutagenesis of binding interfaces to optimize complementarity

  • Energy minimization to identify stable conformations

• Specificity switching:

  • Computational redesign of existing antibodies to change target specificity

  • Focus modifications on CDR regions while maintaining framework stability

  • Balance affinity improvements with stability considerations

• Variant screening:

  • Generate computational libraries of design variants

  • Rank variants based on predicted binding energy and stability

  • Select diverse candidates for experimental validation

This approach has successfully yielded antibodies binding to multiple variants of concern for SARS-CoV-2, including Omicron, Delta, Wuhan, and South African spike protein variants, demonstrating the potential for computational methods to address rapidly evolving targets .

What strategies can resolve common issues in antibody-based flow cytometry experiments?

When troubleshooting flow cytometry experiments using antibodies like RPAT8, researchers should systematically address these common issues:

For optimal results with RPAT8 specifically, maintain proper storage conditions (4°C short-term, -20°C long-term), avoid freeze-thaw cycles, and use the recommended concentration of 0.5 μg per 10^6 cells .

How can researchers ensure reproducibility when working with antibodies across different experimental platforms?

Ensuring reproducibility when working with antibodies across different experimental platforms requires meticulous attention to detail and standardized protocols:

• Comprehensive documentation:

  • Record complete antibody information including clone, catalog number, lot number, and RRID

  • Document exact experimental conditions, including buffers, incubation times, and temperatures

  • Maintain detailed protocols with step-by-step procedures

• Standardization practices:

  • Use calibration standards appropriate for each platform

  • Implement standard operating procedures (SOPs) for all steps

  • Include consistent positive and negative controls across experiments

• Validation across platforms:

  • Validate antibody performance when transitioning between techniques (e.g., from flow cytometry to immunohistochemistry)

  • Determine optimal concentrations for each application independently

  • Consider epitope accessibility differences between applications

• Antibody characterization:

  • Verify antibody specificity using multiple approaches

  • Test for cross-reactivity with similar proteins

  • Consider monoclonal alternatives when reproducibility is paramount

• Data management and sharing:

  • Employ electronic laboratory notebooks with standardized reporting

  • Share detailed methods through repositories or supplementary materials

  • Follow field-specific reporting guidelines

Implementing these practices significantly improves experimental reproducibility and facilitates meaningful comparison of results across different studies and laboratories .